• Explore /
  • Poster
  • / Phase I study of SEA-CD40, gemcitabine, nab-paclitaxel, and pembrolizumab in patients (pts) with metastatic pancreatic ductal adenocarcinoma (PDAC) (trial in progress).

Phase I study of SEA-CD40, gemcitabine, nab-paclitaxel, and pembrolizumab in patients (pts) with metastatic pancreatic ductal adenocarcinoma (PDAC) (trial in progress).

Abstract Video & Slides Poster

Authors

David Bajor

David Lawrence Bajor

Case Western Reserve University/University Hospitals Cleveland Medical Center, Cleveland, OH

David Lawrence Bajor , Martin Gutierrez , Gina M. Vaccaro , Ashiq Masood , Ursa Abigail Brown-Glaberman , Juneko E. Grilley-Olson , Milind M. Javle , Hedy L. Kindler , Olumide B. Gbolahan , Anthony Frank Shields , Mark Zalupski , Michael W. Schmitt , Andrew L. Coveler

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2021 Gastrointestinal Cancers Symposium

Session Type

Trials in Progress Poster Session

Session Title

Trials in Progress Poster Session: Pancreatic Cancer

Track

Pancreatic Cancer

Sub Track

Therapeutics

Clinical Trial Registration Number

NCT02376699

Citation

J Clin Oncol 39, 2021 (suppl 3; abstr TPS451)

DOI

10.1200/JCO.2021.39.3_suppl.TPS451

Abstract #

TPS451

Poster Bd #

Online Only

Abstract Disclosures

Similar Posters

First Author: Andrew L. Coveler

First Author: Andrew L. Coveler

First Author: David Lawrence Bajor

First Author: Johanna C. Bendell